Abstract
Acute lung injury is a life-threating condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-α (TNF-α) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- α co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.
Keywords: Acute lung injury, secretory phospholipase A2, varespladib, surfactant.
Current Pharmaceutical Biotechnology
Title:Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture
Volume: 14 Issue: 4
Author(s): Daniele De Luca, Francesca Vendittelli, Joaquim Trias, Heather Fraser, Angelo Minucci, Leonarda Gentile, Jesus Perez-Gil, Giorgio Conti, Massimo Antonelli and Ettore D. Capoluongo
Affiliation:
Keywords: Acute lung injury, secretory phospholipase A2, varespladib, surfactant.
Abstract: Acute lung injury is a life-threating condition characterized by surfactant dysfunction and raised secretory phospholipase A2 (sPLA2) activity. Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury. We aimed at investigating the effect of co-administration of surfactant and varespladib on sPLA2 activity. Alveolar macrophages were cultured and stimulated with lipopolysaccharide and then treated with either varespladib, surfactant, varespladib followed by surfactant or nothing. sPLA2 activity, free fatty acids, tumour necrosis factor-α (TNF-α) and protein concentrations were measured in culture supernatants. Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures. Surfactant, varespladib and varespladib + surfactant, respectively decreased free fatty acids by -45% (p=0.045), - 62% (p=0.009) and -48% (p=0.015), from the baseline concentration of the untreated cultures. Varespladib and poractant- α co-administration reduces sPLA2 activity and free fatty acids release in cultured rat alveolar macrophages, although a clear drug synergy was not evident. Since co-administration may be useful to reduce inflammation and surfactant inactivation in acute lung injury, further in vivo studies are warranted to verify its clinical usefulness.
Export Options
About this article
Cite this article as:
Luca Daniele De, Vendittelli Francesca, Trias Joaquim, Fraser Heather, Minucci Angelo, Gentile Leonarda, Perez-Gil Jesus, Conti Giorgio, Antonelli Massimo and Capoluongo Ettore D., Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture, Current Pharmaceutical Biotechnology 2013; 14 (4) . https://dx.doi.org/10.2174/1389201011314040010
DOI https://dx.doi.org/10.2174/1389201011314040010 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi Terminal Domain Analyzed by SAR and Computational Mutagenesis
Current Proteomics Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa
Current Medicinal Chemistry COVID-19 and Tuberculosis: Two Knives in a Sheath
Coronaviruses Serial Analysis of Gene Expression (SAGE): 13 Years of Application in Research
Current Pharmaceutical Biotechnology The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Probability Issues in Molecular Design: Predictive and Modeling Ability in 3D-QSAR Schemes
Combinatorial Chemistry & High Throughput Screening Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy
Current Molecular Pharmacology Genomic Characterization of Emerging SARS-CoV-2: A Systematic Review
Current Bioinformatics Meet Our Section Editor
Recent Advances in Anti-Infective Drug Discovery COVID-19 and Coinfections: A Serious Health Threat Requires Combination of Diagnosis and Therapy
Infectious Disorders - Drug Targets Nanoantioxidant/Antioxidant Therapy in 2019-nCoV: A New Approach to Reactive Oxygen Species Mechanisms
Current Drug Therapy A Concept of Homeostatic Inflammation Provided by Endogenous TLR4 Agonists that Function Before and After Danger Signal for Metastasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine Novel Strategies for Combating Pathogenic Biofilms Using Plant Products and Microbial Antibiosis
Current Pharmaceutical Biotechnology Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Combination Therapy with Favipiravir for Treatment of Hospitalized COVID-19 Adults
New Emirates Medical Journal The Role of CO-RADS Scoring System in the Diagnosis of COVID-19 Infection and its Correlation with Clinical Signs
Current Medical Imaging